Columns The MS Wire - A Column by Ed Tobias Cholesterol Medication Shows Promise as MS Treatment Cholesterol Medication Shows Promise as MS Treatment by Ed Tobias | May 12, 2017 Share this article: Share article via email Copy article link I’ve been taking a statin drug for years to keep my cholesterol low, and it’s doing a really good job. Now, there’s hope that this class of drug also might be useful for MS patients. A major trial in the U.K. is testing the drug simvastatin (used to control cholesterol under the brand name Zocor) for use in halting the progression of secondary progressive multiple sclerosis. Simvastatin is an inexpensive statin, similar to the atorvastatin (brand name Lipitor) that I use to keep my cholesterol in check. The trial is a follow-up to a Phase 2 clinical trial of simvastatin that involved 140 people with SPMS. That study was published in The Lancet in 2014. Phase 2 research found that MS patients taking high doses of simvastatin had a significant reduction in their rate of brain atrophy over two years. The patients also had better disability and quality-of-life scores at the end of the study. Simvastatin ‘holds incredible promise’ Phase 3 research is being led by Jeremy Chataway, MA, PhD, of the University College London’s (UCL) Institute of Neurology. Chataway alsoĀ led simvastatin’s Phase 2 trial. “This drug holds incredible promise for the thousands of people living with secondary progressive MS in the U.K., and around the world, who currently have few options for treatments that have an effect on disability,” Chataway said, according to UCL’s website. “This study will establish definitively whether simvastatin is able to slow the rate of disability progression over a three-year period, and we are very hopeful it will.” The research, expected to cost about $7 million, is being funded by a collaboration of the U.S. National Multiple Sclerosis Society, the U.K. Multiple Sclerosis Society, the U.K. National Institute for Health Research, the U.K. National Health Service and U.K. universities. Patient thinks it’s ‘absolutely exciting’ In a National MS Society news release, SPMS patient Susan Stellmacher of Minneapolis, Minnesota, said, “I think it’s absolutely exciting news. There has been nothing for me, ā¦ so to think that something so widely available and more affordable is possible, that’s exciting.” That possibility is exciting for a lot of us, Susan. We’ll be watching with great interest, even though research results will be a long time coming. The trial, which involves 1,180 people with SPMS across the U.K., will take six years to complete. *** Note:Ā Multiple Sclerosis News TodayĀ is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those ofĀ Multiple Sclerosis News TodayĀ or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.Ā Follow my personal blog at: www.themswire.com. Print This Page About the Author Ed Tobias People say to write what you know and Ed Tobias knows about MS. He's lived with the illness since 1980, when he was 32 years old. Ed's a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. Heās also the author of āThe Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.ā Ed and his wife split their time between the Washington, D.C. suburbs and Floridaās Gulf Coast, trying to follow the sun. Tags cholesterol, MS treatments, multiple sclerosis, simvastatin Comments Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study
April 24, 2024 News by Andrea Lobo, PhD Foralumab found to ease fatigue in SPMS patients in access program